The interferon lambda family (IFN-l1/2/3) is a newly described group of cytokines that are related to both the type-1 interferons and IL-10 family members. These novel cytokines are induced during viral infection and, like type-1 interferons, display significant anti-viral activity. In order to understand their function in more depth, we have examined the ability of IFN-l1/IL-29 to regulate cytokine production by human immune cells. Whole peripheral blood mononuclear cells (PBMC) exposed to IFN-l1 specifically upregulated IL-6, -8 and -10 but there were no visible effects on TNF or IL-1. This response was produced in a dose-dependant fashion and was inhibited by IL-10. Examination of purified cell populations isolated from PBMC demonstrated that monocytes, rather than lymphocytes, were the major IFN-l1-responsive cellular subset, producing IL-6, -8 and -10 in response to IFN-l1. Monocyte responses induced by low-level LPS stimulation were also synergistically enhanced by the presence of IFN-l1. Human macrophages were also shown to react to IFN-l1 similarly to monocytes, by producing the cytokines IL-6, -8 and -10. In conclusion, we have shown that IFN-l1, a cytokine produced in response to viral infection, activates both monocytes and macrophages producing a restricted panel of cytokines and may therefore be important in activating innate immune responses at the site of viral infection.
Introduction
The interferons lambda are a newly described family of cytokines, related to both type-1 interferons and IL-10 family members. 1, 2 The family, classified as the 'type-3' interferons, is comprised of three novel four helical bundle cytokines designated IFN-l1/2/3 (also referred to as IL-29, 28A and 28B, respectively 2 ). All three interferons lambda signal through a heterodimeric receptor complex composed of the class II cytokine receptors CRF2-12 (IFN-lambdaR1/IL-28Ra) and CRF2-4 (IL-10RB/IL-10R2). 1, 3 This receptor is quite distinct from that used by type-1 interferons, with the use of the IL-10R2 chain suggesting the similarities with IL-10. 1 IFN-l1/2/3-induced receptor heterodimerization results in the phosphorylation of STAT1 and STAT2, and activation of the ISGF3 transcription complex. 1, 4 These signaling functions are common to those induced by the type-1 interferons (although in the case of the type-1 interferons STAT phosphorylation is through the interferon-a receptor 2) 5 . As with type-1 interferons, expression of interferons lambda is induced by the presence of viral infections; indeed, the molecules display significant anti-viral activity.
1,2 IFN-l1 displays growth inhibitory activity on mouse lymphoma cells that have been engineered to express the IL-28R but does not inhibit the growth of the human Daudi EBV-transformed cells, despite their being strongly growth-inhibited by the type-1 interferons. 6 Similarly, the IFN-l1/2/3 anti-viral activity is observed in fewer cell lines than those protected by type-1 interferons. 7 Thus, although type-1 interferons display potent anti-growth activity and antiviral activity, IFN-l1/2/3 may act in a more cell-specific fashion than the broadly active type-1 interferons.
The presence of both interferon lambda receptor subunits (IL-28Ra and IL-10R2) on many cells of the immune system led us to hypothesize that the interferons lambda have the potential to regulate immunity directly. Given this receptor distribution, immune responses regulated by the interferons lambda are likely to be many and varied, as is the case for both the type-1 interferons and IL-10. Functions of IL-10 include promotion of B-cell survival, growth and differentiation, suppression of inflammatory cytokine synthesis by monocytes and macrophages and the downregulation of T-cell responses, both directly and through effects on dendritic cells. [8] [9] [10] [11] [12] Type-1 interferons also display numerous immune functions other than the anti-viral and antigrowth activities, affecting B cells, NK cells, T helper and dendritic cell functions and playing a pivotal role at the interface between innate and adaptive immunity. [13] [14] [15] In the present study, we have examined the ability of IFN-l1 to induce or modulate a panel of cytokines produced by human immune cells. The data provide insight to the pleiotropic effects of this novel family of molecules in regulating immunity and suggest that in addition to their recognized anti-viral activities, the interferons lambda act to regulate subsequent adaptive immunity following initial innate recognition of pathogens.
Results
IFN-l1 induces IL-6, -8 and -10 in human PBMC Initially, we examined the cytokine profile produced by human PBMC in response to IFN-l1 ( Figure 1a ) and compared it to that obtained following LPS stimulation (Figure 1b) . Whereas, LPS induced IL-1, -6, -8, -10 and TNF, IFN-l1 specifically induced only IL-6, -8 and a small amount of IL-10. The balance of these three cytokines has been shown to be of key importance in the outcome of human sepsis. [16] [17] [18] Neither IL-1 nor TNF was produced in response to IFN-l1, indicating a qualitative difference between this response and that to LPS. The IFN-l1 protein was produced to be free of endotoxin and was dissolved in endotoxin-free medium. We demonstrated that heat inactivation of the IFN-l1 protein (951C for 10 min) abrogated the observed functional response (Figure 1c) , whereas functional effects of LPS could not be destroyed using this method (Figure 1d ). Unstimulated cells produced little or no cytokine (Figure 1e ), comparable to that from those exposed to heat-denatured IFN-l1.
We next chose to study the cytokines IL-6 and -10 further, as they are known to be key modulators of T-cell function and thus may point toward a role for IFN-l1 linking innate and adaptive immunity. The doseresponse curves for IFN-l1 inducing IL-6 and -10 showed that IFN-l1 began to have its effects at 50-100 ng/ml with levels increasing dose-dependently (Figure 2a and b) . Kinetics of IL-6 and -10 production in response to IFN-l1 showed detectable IL-6 and -10 within 6 h of culture, with levels rising thereafter, through to 72 h post-stimulation (Figure 2c and d) .
IL-10 acts as an antagonist to IFN-l1 function
We examined the IL-6-response to IFN-l1 in the presence of a blocking anti-10 monoclonal antibody ( Figure 3 ). Blocking antibodies directed against IL-10 increased the levels of IL-6 induced by IFN-l1 considerably while isotype control antibodies had no effect (Figure 3a) . Moreover, the inclusion of blocking anti-IL-10 antibodies led to IFN-l1 effects occurring at a much lower dose. Thus, in the presence of anti-IL-10, IFN-l1 was able to induce half-maximal IL-6 production at a 10-to 100-fold lower concentration than using IFN-l1 alone (Figure 3b ). Addition of IL-10 at 10 ng/ml before the addition of IFN-l1 to the culture resulted in the abrogation of the IFN-l1-induced IL-6 response (Figure 3b) .
Regulation of the novel IL-10 homologue IL-19 by IFN-l1 IL-19 is a novel member of the IL-10 family of cytokines. It is secreted by monocytes in response to cytokine or inflammatory stimuli 19 and is important in the generation of Th2 responses; [20] [21] [22] like IFN-l1, the actions of IL-19 are inhibited by IL-10. 23 We investigated the Human PBMC were cultured for 18 h in the presence of recombinant IFN-l1 and supernatants examined for levels of IL-4, -13, IFN-g, IL-1-a, IL-6, -8, -10 and TNF using ELISA (a). The cytokine response to LPS was also examined as a positive control (b). IFN-l1-stimulated PBMC produced high levels of IL-6 and -8 and moderate levels of IL-10 (a), whilst LPS-stimulation (100 ng/ml) produced a broader response, stimulating IL-1, -6, -8, -10 and TNF (b). Bioactivity of IFN-l1 was destroyed by subjecting the cytokine to protein-denaturing conditions (heating to 951C for 10 min) before adding to the culture, resulting in loss of its ability to induce IL-6, -8 and -10 (c). Cells treated with LPS that had been subjected to heating at 951C for 10 min produced a full cytokine response (d). Unstimulated cells did not produce a measurable cytokine response (e). Results are from one single experiment with similar results being observed in four independent experiments; means7s.d. are shown. 
IFN-l1 is an activator of monocyte responses
To examine the cellular target for IFN-l1 within the PBMC population, we looked at its effect on highly enriched T cell, B cell and monocyte subsets ( Figure 5 ). 
IFN-l1 enhances the cytokine response to LPS in monocytes
In order to investigate the effects of IFN-l1 during a classical pattern-recognition initiated monocyte-driven response, we chose to examine its ability to regulate cytokine response to LPS ( Figure 6 ). Responses to LPS induced high levels of IL-6, -8 and -10 from PBMC even at the relatively low dose of 1 ng/ml. At low doses of LPS, IFN-l1 had a synergistic effect on the cytokine response, increasing levels of IL-6, -8 and -10. This effect was most apparent for IL-6 and -8. IFN-l1 did not display this synergistic effect on these cytokines when high levels of LPS (100 ng/ml) were used.
IFN-l1 induced IL-6, -8 and -10 in human macrophages
Given the stimulatory effect of IFN-l1 on isolated human monocytes, it was of interest to determine whether such effects would be present on mature macrophages. Isolated monocytes were encouraged to mature into macrophages by culturing for 8 days in autologous serum. Macrophages developed in this way were previously shown to undertake phagocytosis, ROI release and to be capable of expressing IFNg and iNOS. They were then exposed to IFN-l1 and supernatants harvested over a 32 h period. Following analysis by ELISA, it was apparent that human macrophages are also responsive to IFN-l1 ( Figure 7 ).
Discussion
Type-1 interferons produced early on during infection play a vital role in directing an appropriate immune response, leading to effective clearance of the pathogen. The role of these interferons is twofold: firstly, they have strong, anti-viral properties, killing cells infected with virus and inhibiting growth to prevent viral spread; secondly, they act as messenger molecules to initiate effective adaptive immune response. Thus, type-1 interferons link the innate and adaptive arms of the immune response in a process that is instigated almost immediately following initial recognition of pathogen surface molecules through pattern recognition molecules such as the toll-like receptors (TLRs). This recognition induces interferon production that promotes and regulates antigen uptake, processing and presenting to T cells, thereby directing an appropriate adaptive response.
14,24-31
The discovery of the CRF2-12 molecule through its homology with the a-chain of the IL-22 receptor, together with the presentation of an orphan ligand related to the a interferons ('Zcyto21') 32 came together to define a novel family of cytokines related to type-1 interferons, the lambda interferons (IFN-l1/2/3). 1 A parallel effort led to these ligands being characterized as IL-29, -28A and -28B, respectively. 2 These novel ligands have anti-viral activity, in common with the type-1 interferons. They are structurally related to both the type-1 interferons and the IL-10 family Figure 7 Macrophage cytokines induced though exposure to IFNl1. Macrophages were generated from purified monocytes, washed and exposed to IFN-l1 over a period of 32 h with supernatants harvested at various time points during the experiment. Supernatants were then assessed for levels of IL-6 (a), IL-8 (b) and IL-10 (c) using ELISA. Similar results were observed in three independent experiments; means7s.d. are shown.
composed of two subunits: the novel CRF2-12 (IFN-lR1/ IL28Ra) and the CRF2-4 (the IL-10Rb chain) that is shared by the IL-10, -22 and -26 receptor complexes. As with type-1 interferons, interferons lambda display both anti-viral and growth inhibitory properties, with signaling pathways (ISGF3 and STAT1 and STAT2 activation) that are also induced following type-1 interferon stimulation.
We anticipated that as with the structurally related type-1 interferons and IL-10, IFN-l1 would display a range of effects on immune cells. Our initial data showed IFN-l1 inducing a strong IL-6 and -8 secretory response along with moderate levels of IL-10 from PBMC. As expected in a study looking at response effects in PBMC from numerous donors, the actual levels of cytokines secreted varied widely, but the pattern of secretion was similar from donor to donor. 33 This IFN-l1-induced cytokine profile appears to be quite distinct from that induced by type-1 interferons, LPS and IL-10. The ratios of IL-10:IL-6 and IL-10:IL-8 are important to the outcome of sepsis or trauma, with low ratios (i.e. high IL-10 relative to IL6 or IL-8) associated with detrimental outcome. [16] [17] [18] The induction of IL-8, a chemoattractant for neutrophils, suggests a role in early recruitment of inflammatory cells to the site of infection and whilst both IL-6 and -10 are known mainly for their roles in the adaptive immune system, both also have roles in innate responses. [34] [35] [36] [37] The presence of IL-6 and -10 was particularly interesting from the perspective of IFN-l1 playing a role in linking innate and adaptive immunity. IL-6 plays a key role in the transition from a response dominated by cells of the innate immune system into one capable of mounting subsequent adaptive immunity, promoting the transition from a neutrophil-mediated infiltrate into one of monocytes, macrophages and lymphocytes. 38, 39 Thus, release of IFN-l1 that occurs following viral infection may be a critical factor in establishing a cellmediated response, possibly in part through the action of IL-6. Likewise, the production of IL-10 in response to IFN-l1 is also likely to play a role in cell-mediated immune-modulation. 40, 41 Functions of IL-10 include promotion of B-cell survival, growth and differentiation, [42] [43] [44] [45] suppression of inflammatory cytokine synthesis by monocytes and macrophages and the downregulation of T-cell responses, both directly and through effects on dendritic cells. [8] [9] [10] [11] [12] IL-10 has also been implicated in the generation and maintenance of regulatory T cells, further emphasizing its important role in immune regulation. 46, 47 Examination of dose-response curves revealed that a high dose of IFN-l1 was required for effects. This doseresponse is consistent with other known functions of the IFN-l family members, such as their anti-viral and growth inhibition effects, 1, 7 where IFN-l has been observed to have its effects at between 10-and 100-fold greater doses than IFN-a2a. 1 The reason for the high dose requirement in anti-viral studies is not known, but may be due to low levels of receptor expression, a required synergy with other proteins for maximal effect, a high sensitivity to anti-inflammatory molecules that suppress its action or simply that highly bioactive IFN-l is difficult to manufacture.
We investigated whether blocking IL-10 would have an effect on the IFN-l1-induced IL-6 response as it is known to be highly anti-inflammatory and may be acting so as to regulate this response. The data showed that in the presence of blocking anti-IL-10 antibodies, IFN-l1 was able to induce more IL-6. Moreover, this blocking antibody greatly reduced the dose required for IL-6 production in response to IFN-l1, suggesting tight control of IFN-l1 action by IL-10. In the presence of blocking anti-IL-10 antibodies, IFN-l1 was able to act at concentrations more in line with those observed for other type-1 interferons, displaying half-maximal effects at between 20 and 50 ng/ml. As expected, addition of IL-10 to cultures suppressed the response to IFN-l1. The fact that IFN-l1 induces IL-10 and that the effects of IFN-l1 are particularly sensitive to the action of IL-10, suggests that there is a highly sensitive, IL-10 dependent feedback mechanism, which regulates the function of IFN-l1. However, as both IL-10 and IFN-l1 utilize the IL-10R2 common chain it is also possible that IL-10 binding to the IL-10R2 results in a reduced capacity for IFN-l1 to bind to or signal through its receptor complex, perhaps through competition for the IL-10R2 chain. Volk et al. 48 have shown in a study involving monocytes and hepatocytes that there was no competition for IL-10R2 chain binding when looking at the effects of IL-10 and -22, both of which have IL-10R2 as part of their receptor complexes.
We were also interested as to whether IFN-l1 could induce the recently discovered member of the IL-10 family of cytokines, IL-19. The role of IL-19 in cytokine responses appears complex with functions including the promotion of Th2 cytokines as well as IL-10, [19] [20] [21] [22] [23] yet also displaying an association with psoriasis, 49-51 a Th1-associated chronic inflammatory disease. IFN-l1 was able to induce increased levels of IL-19 mRNA in whole PBMC, although the response was low in comparison to that induced by LPS. IFN-l1 was not able to upregulate levels of IL-19 mRNA induced by LPS. The results add to an overall picture that IFN-l1 regulates a cytokine profile that is complex and includes increases in the Th2-associated cytokines IL-6 and -19.
In order to determine the cell type that was being affected in our PBMC cultures we examined highly purified T, B and monocytes isolated from PBMC. Examination of IL-6 secretion indicated that it was the monocyte population that was being affected. Furthermore, we noted that monocytes under the influence of IFN-l1 began to change shape, becoming larger and elongated and migrating into focal points within the tissue culture plate. Thus, it may be that IFN-l1 plays a role in chemotaxis and although we have not yet explored this possibility in any detail, it may be as a result of the IL-8 production that we observed in response to IFN-l1.
We finally chose to examine whether IFN-l1 could affect cytokine production during a response to LPS ( Figure 6 ) in order to assess whether it can affect classical pattern-recognition initiated monocyte-driven responses. IFN-l1 was consistently able to increase monocyte cytokine responses to relatively low levels of LPS (1 ng/ml). This effect was synergistic, rather than additive and was most apparent for IL-6 and -8, rather than IL-10 response. Under conditions where LPS was used at a much higher does (100 ng/ml), IFN-l1 did not increase the IL-6 and -8 response further. It is likely that monocytes given such a high level of LPS reach their maximal cytokine-producing capacity and thus cannot be modulated any further under those conditions. The data indicate that one function of IFN-l1 could be to enhance early responses to small amounts of inflammatory material. Given that the IFN-l1 response is sensitive to the action of endogenous IL-10, it appears that there is a high level of regulation in order to prevent inappropriate/unwanted exacerbation of chronic low-level inflammation.
In conclusion, we present the ability of IFN-l1 to elicit a restricted panel of cytokines, IL-6, -8 and -10, from human immune cells, particularly monocytes. Its actions on monocytes included morphological and motility changes, and the induction if IL-19 mRNA. These actions are tempered by endogenous and exogenous IL-10 and place IFN-l1 as a potential new key regulator of monocyte, macrophage and leukocyte function, potentially capable of stimulating the recruitment and activation of immune cells to the site of viral infection.
Materials and methods

Cells
Peripheral blood mononuclear cells (PBMC) were isolated from anonymous buffy coats purchased from the Newark Blood Bank, by density-gradient centrifugation over 'Histopaque-1077' (Sigma, St Louis, MO, USA). Monocytes, B cells and T cells were prepared from PBMC using the MACS system (Miltenyi Biotech, Auburn, CA, USA). CD14 and CD19 magnetic bead selections were used to positively select monocytes and B cells, respectively, according to the manufacturer's instructions, leading to observed purity of 98 and 95%, respectively. CD14/CD19-depleted PBMC were used to enrich 'untouched' T cells using the 'Pan T-Cell isolation kit II' (removing cells expressing CD14, CD16, CD19, CD36, CD56, CD123 and glycophorin A), as per the manufacturer's instructions, with purity being over 98%. Macrophages were generated from purified peripheral blood monocytes thus; briefly, monocytes (5 Â 10 5 ) were first allowed to adhere to the surface of 12-well plates, washed and grown for 8 days in the presence of 10% autologous serum. The resultant macrophages were then washed and stimulated to examine their response to IFN-l1.
Culture conditions
Culture medium consisted of RPMI 1640 medium, supplemented with 10% FCS and penicillin and streptomycin at 100 IU/ml and 100 mg/ml, respectively (all from Sigma). For dose-response experiments, whole PBMC were cultured in 96-well, flat-bottomed plates (2 Â 10 5 in 200 ml) for 18 h over a range of IFN-l1 concentrations (Peprotech, Rocky Hill, NJ, USA), as shown. For all other experiments PBMC were cultured in 24-well plates at 2 Â 10 6 cells in 2 ml in the presence or absence of human recombinant IFN-l1 at 1 mg/ml. For antibody blocking experiments, cells were pre-incubated for 1 h with ratanti-human-IL-10 (clone 9D7) or isotype control MAb MOPC-21 (BD Pharmingen, San Jose, CA, USA) at a concentration of 10 mg/ml before addition of IFN-l1. In some experiments IL-10 (Peprotech) was added to cultures at 10 ng/ml. During LPS stimulations, whole PBMC were incubated in 24-well plates, using 1 Â 10 6 cells in 2 ml either with or without IFN-l1 for 30 min before addition of LPS to the final concentrations as indicated in the figures. Supernatants were harvested and frozen at À801C for later cytokine analysis by ELISA and cell pellets harvested, washed in PBS and total RNA extracted (Stratagene, La Jolla, CA, USA) for later RT-PCR analysis.
Measurement of cytokine protein
Cytokine levels within supernatants were measured using ELISA. Paired antibodies consisting of purified capture and biotinylated secondary detection antibodies purchased from BD Pharmingen were used according to the manufacturer's recommendations. Standards were purchased from Peprotech. The ELISA protocols were as previously described. 52 Gene expression analysis Total RNA was extracted from PBMC using the Stratagene 'Absolutely RNA' kit (Stratagene, La Jolla, CA, USA), whilst cDNA generation and real time PCR was performed using the TaqMan Gold RT-PCR kit with SYBR Green I chemistry (ABI, Foster City, CA, USA). Primers for IL-19 cDNA amplification were: TCTGCGGCAATGTCAGGAA (sense) and GGACCTC CAGCTGATCATAGTTGT (anti-sense). For HPRT cDNA amplification, primers used were: CAGCCCTGGCGT CGTGATTAGT (sense) and GCAAGACGTTCAGTCC TGTCCATAA (anti-sense). Gene amplification was performed using the MX4000 multiplex quantitative PCR system (Stratagene, CA, USA). PCR conditions consisted of an initial denaturation step of 951C for 10 min, followed by 45 cycles of 951C for 30 s, and 601C for 1 min. A melting temperature assay (MTA) was performed on amplicons in order to assess the fidelity of the amplification. Quantitative assessment of IL-19 and -10 mRNA expression was performed as previously described, 23 based on the method described by Langenkamp et al. 53 Levels of cytokine mRNA were obtained by measuring target mRNA C t values (IL-19) as relative to C t values of the housekeeping gene HPRT. Results were then expressed as 'fold-increase' over controls within each experiment (i.e. fold-increase of cytokine mRNA expression in IL-19-treated cultures in relation to untreated controls).
